{'52WeekChange': 1.0918367,
 'SandP52WeekChange': None,
 'address1': '10260 Bubb Road',
 'algorithm': None,
 'annualHoldingsTurnover': None,
 'annualReportExpenseRatio': None,
 'ask': 2.02,
 'askSize': 3100,
 'averageDailyVolume10Day': 955337,
 'averageVolume': 1683569,
 'averageVolume10days': 955337,
 'beta': 2.162464,
 'beta3Year': None,
 'bid': 2.01,
 'bidSize': 4000,
 'bookValue': 0.072,
 'category': None,
 'circulatingSupply': None,
 'city': 'Cupertino',
 'companyOfficers': [],
 'country': 'United States',
 'currency': 'USD',
 'dateShortInterest': 1593475200,
 'dayHigh': 2.07,
 'dayLow': 2.005,
 'dividendRate': None,
 'dividendYield': None,
 'earningsQuarterlyGrowth': None,
 'enterpriseToEbitda': -16.526,
 'enterpriseToRevenue': 13.055,
 'enterpriseValue': 368269440,
 'exDividendDate': None,
 'exchange': 'NCM',
 'exchangeTimezoneName': 'America/New_York',
 'exchangeTimezoneShortName': 'EDT',
 'expireDate': None,
 'fax': '408-777-3577',
 'fiftyDayAverage': 2.2654285,
 'fiftyTwoWeekHigh': 3.95,
 'fiftyTwoWeekLow': 0.94,
 'fiveYearAverageReturn': None,
 'fiveYearAvgDividendYield': None,
 'floatShares': 173166169,
 'forwardEps': -0.21,
 'forwardPE': -9.571429,
 'fromCurrency': None,
 'fullTimeEmployees': 87,
 'fundFamily': None,
 'fundInceptionDate': None,
 'gmtOffSetMilliseconds': '-14400000',
 'headSymbol': None,
 'heldPercentInsiders': 0.033010002,
 'heldPercentInstitutions': 0.46598998,
 'industry': 'Drug Manufacturers—Specialty & Generic',
 'isEsgPopulated': False,
 'lastCapGain': None,
 'lastDividendValue': None,
 'lastFiscalYearEnd': 1577750400,
 'lastMarket': None,
 'lastSplitDate': None,
 'lastSplitFactor': None,
 'legalType': None,
 'logo_url': 'https://logo.clearbit.com/durect.com',
 'longBusinessSummary': 'DURECT Corporation, a biopharmaceutical company, '
                        'researches and develops medicines based on its '
                        'epigenetic regulator and pharmaceutical programs. The '
                        'company offers ALZET product line that consists of '
                        'osmotic pumps and accessories used for experimental '
                        'research in mice, rats, and other laboratory animals; '
                        'and a range of biodegradable polymers for '
                        'pharmaceutical and medical device clients for use as '
                        'raw materials in their products under the LACTEL '
                        'brand. Its product pipeline consists of multiple '
                        'investigational drug candidates in development, such '
                        'as DUR-928, an endogenous, orally bioavailable small '
                        'molecule that is in Phase I and II development stage '
                        'to play a regulatory role in lipid homeostasis, '
                        "inflammation, and cell survival. The company's oral "
                        'and injectable delivery technologies are designed to '
                        'enable new indications and enhanced attributes for '
                        'small-molecule and biologic drugs, including POSIMIR, '
                        'an investigational analgesic product intended to '
                        'deliver bupivacaine to provide up to 3 days of pain '
                        'relief after surgery. DURECT Corporation markets and '
                        'sells its ALZET and LACTEL product lines through '
                        'direct sales force in the United States, as well as '
                        'through a network of distributors in Japan, Europe, '
                        'and internationally. The company has strategic '
                        'collaboration and other agreements with Virginia '
                        'Commonwealth University Intellectual Property '
                        'Foundation; Indivior UK Ltd.; Santen Pharmaceutical '
                        'Co., Ltd.; Sandoz AG; and Zogenix, Inc. DURECT '
                        'Corporation was founded in 1998 and is headquartered '
                        'in Cupertino, California.',
 'longName': 'DURECT Corporation',
 'market': 'us_market',
 'marketCap': 394010240,
 'maxAge': 1,
 'maxSupply': None,
 'messageBoardId': 'finmb_27768',
 'morningStarOverallRating': None,
 'morningStarRiskRating': None,
 'mostRecentQuarter': 1585612800,
 'navPrice': None,
 'netIncomeToCommon': -23396000,
 'nextFiscalYearEnd': 1640908800,
 'open': 2.04,
 'openInterest': None,
 'payoutRatio': 0,
 'pegRatio': -0.91,
 'phone': '408-777-1417',
 'previousClose': 2.05,
 'priceHint': 4,
 'priceToBook': 27.916668,
 'priceToSalesTrailing12Months': 13.968032,
 'profitMargins': -0.82941,
 'quoteType': 'EQUITY',
 'regularMarketDayHigh': 2.07,
 'regularMarketDayLow': 2.005,
 'regularMarketOpen': 2.04,
 'regularMarketPreviousClose': 2.05,
 'regularMarketPrice': 2.04,
 'regularMarketVolume': 680892,
 'revenueQuarterlyGrowth': None,
 'sector': 'Healthcare',
 'sharesOutstanding': 196024992,
 'sharesPercentSharesOut': 0.0792,
 'sharesShort': 15524271,
 'sharesShortPreviousMonthDate': 1590710400,
 'sharesShortPriorMonth': 5916320,
 'shortName': 'DURECT Corporation',
 'shortPercentOfFloat': 0.0917,
 'shortRatio': 5.93,
 'startDate': None,
 'state': 'CA',
 'strikePrice': None,
 'symbol': 'DRRX',
 'threeYearAverageReturn': None,
 'totalAssets': None,
 'tradeable': False,
 'trailingAnnualDividendRate': None,
 'trailingAnnualDividendYield': None,
 'trailingEps': -0.132,
 'twoHundredDayAverage': 2.0584173,
 'underlyingExchangeSymbol': None,
 'underlyingSymbol': None,
 'uuid': 'e77ce79d-8bdf-33c2-8d1b-fd9ac415ef17',
 'volume': 680892,
 'volume24Hr': None,
 'volumeAllCurrencies': None,
 'website': 'http://www.durect.com',
 'yield': None,
 'ytdReturn': None,
 'zip': '95014'}